Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible by Gerald B Fogarty et al.
Fogarty et al. BMC Research Notes 2014, 7:412
http://www.biomedcentral.com/1756-0500/7/412RESEARCH ARTICLE Open AccessAccrual to a randomised trial of adjuvant whole
brain radiotherapy for treatment of melanoma
brain metastases is feasible
Gerald B Fogarty1,2,6*, Angela Hong1,2,6, Kari Dolven Jacobsen3, Claudius H Reisse3, Brindha Shivalingam1,2,
Bryan Burmeister5,6, Lauren E Haydu1,4, Elizabeth Paton4 and John F Thompson1,2Abstract
Background: Brain metastases (BMs) are common in melanoma patients. Adjuvant whole brain radiotherapy (WBRT)
following local treatment of intracranial melanoma metastases with neurosurgery and/or stereotactic radiosurgery is
controversial. A randomised trial is needed. However, accrual to WBRT trials has been problematic. A pilot study by
Australia and New Zealand Melanoma Trials Group (ANZMTG) was conducted to see if accrual was feasible.
Methods: Sites canvassed for interest included those who treat melanoma patients, had a proven accrual in previous
melanoma trials and who had the relevant infrastructure support. Feasibility forecasts from interested sites were sought.
These were compared to the patient numbers documented in the research contracts. A target accrual of 60 patients in
2 years was set. Funding was sought for the pilot study. Basic demographics of the pilot study cohort were collected.
Results: The first centre opened December 2008; the first patient was randomised in April 2009. The pilot accruing
period concluded in September, 2011. In 30 months, 54 patients from 10 of a total of 17 activated sites in Australia
(39, 72%) and in Norway (15, 28%) had been accrued. Feasibility forecasts predicted 133 trial eligible patients per year
(including 108 Australian + 25 International patients). Site estimates generally overestimated accrual with 4 of 17 active
sites estimating within 50% of target numbers. Sites with patient estimates calculated from records were more accurate
than those estimated from memory. The overall recruitment target was lower in the research contracts when
compared to the feasibility evaluation. Basic demographics of the pilot study revealed 62% of patients were males; 58%
had a single metastasis, 28% had two and 14% had three metastases. 12-month overall survival was 50%.
Conclusions: Despite only 54 patients and not the full 60 patient target being accrued in two years the Trial
Management Committee and Data Safely Monitoring Committee approved the continuation of the pilot study to the
main trial. On the basis of this successful pilot study, funding was achieved for the full study. 143 patients of a target of
200 have been randomised by June 2014.
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Randomised trialBackground
Brain metastases (BMs) are common in patients with
metastatic melanoma [1,2] and are the cause of death in
the majority of them [2,3]. Whole brain radiotherapy
(WBRT) is a common adjuvant treatment after local treat-
ment of BMs with neurosurgery and/or stereotactic* Correspondence: Gerald.fogarty@cancer.com.au
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unless otherwise stated.radiation (SR). However, there is no level one evidence to
support this approach in melanoma. Proponents say that
WBRT improves palliation by prolonging intracerebral con-
trol [4]. Opponents say that WBRT does not increase sur-
vival, may cause neurocognitive problems and may not
prevent intracerebral progression [5,6]. A randomised con-
trolled trial (RCT) is needed to resolve this controversy.
Based on trials of WBRT in BMs of all histologies, an ac-
crual target of two hundred patients for the RCT was con-
sidered necessary, and a protocol was developed [7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lematic. Trials of WBRT for BMs in all histologies have
taken many years to accrue [8-10]. Some have even closed
prematurely [11,12] (Table 1). The majority of these trials
also had no or inappropriate tests for neurocognitive func-
tion (NCF), an important endpoint in this scenario. Mean-
ingful NCF testing takes time and requires expertise, and
therefore has funding implications.
In order to ensure that a RCT of WBRT in melanoma
could be completed, a pilot study was designed. The pur-
pose of the study was to assess whether accrual to the
main trial was feasible. The pilot study was designed to
flow on to the main trial, so that if the pilot was successful,
the patients accrued would automatically become part of
the main study.
Methods
This trial is an international multi-centre, open-label,
stratified, 2-arm randomised phase III trial. The trial has
been approved by the Cancer Institute NSW Clinical
Research Ethics Committee #2007C/11/032 and relevant
hospital ethics committees in each participating centre.
Written informed consent for participation in the study
was obtained from participants.
Initially, attention during the pilot study was aimed at
finding sites interested in contributing patients and can-
vassing their opinion as to whether this was a trial that
they considered worthwhile.
Sites
Sites canvassed included those with a proven accrual
record in previous melanoma trials; were sites that
treated patients with melanoma brain metastases; wereTable 1 Accrual to whole brain radiotherapy trials




Patchell et al. [8] WBRT vs. OBS All solid tumours (mainly lung)
Sol BM post- surgery
Aoyama et al. [9] SR vs. WBRT + SRS All solid tumours
(mainly lung) 1–4 BMs
Kocher et al. [10] SR vs. SR +WBRT All solid tumours
(mainly lung) 1–3 BMs
Chang et al. [11] SR vs. WBRT + SR All solid tumours
(mainly lung) 1–3 BMs
Roos et al. [12]* WBRT vs. OBS All solid tumours sol
BM post-SR/surgery
This study WBRT vs. observation Melanoma only 1–3
BMs post-SR/surgery
WBRT - Whole Brain Radiotherapy.
SR - Stereotactic Radiosurgery.
Sol BM - solitary Brain Metastases.
OBS- observation.
NCF - Neurocognitive.
*Early closure due to poor accrual.sites that had available neurosurgery and/or SR, were
sites adequately resourced to engage in research; and
had functioning melanoma multidisciplinary clinics.
Feasibility forecasts
Feasibility forecasts from interested sites were sought.
From this information, and with the knowledge of the
difficulty of accrual to WBRT trials of all histologies,
and the needs of funding agencies, a target accrual of 60
patients in 2 years was set for the pilot study. This time
frame took into account the customary slow start up
time for new trials, which includes time for administra-
tive arrangements to be made and for staff education.
Sites were then encouraged and assisted to open the trial
in a timely fashion. Activated sites were also required to
sign a research contract to accrue to the trial as part of the
usual trial governance. This contract also asked for a pre-
diction of recruitment. The numbers predicted in the
feasibility forecasts were able to be compared with those
predicted in the research contract. The success of the
study was to be judged by the Trial Management Commit-
tee. However, the real test of whether the study was suc-
cessful would be whether accrual to the pilot study would
convince the funding authority to allocate sufficient funds
for the main trial.
Funding
Funding from the Australia and New Zealand Melan-
oma Trials Group (ANZMTG), Trans-Tasman Radiation
Oncology Group (TROG), The University of Sydney and
the Australian Government’s National Health and Medical











No 96/8 years 12 2 (2%)
No 132/4 years 33 Unknown
No 359/11 years 33 18 (5%)
Yes 58/6 years 10 Early closure 7 patients (12%)
No 19/3 years 6 3 (16%)
Yes 54/2 years 27 54 (100%)
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The first recruiting centre was opened in December 2008,
with the first trial patient being randomised in April 2009.
The pilot grant reporting period concluded on 30th June
2011. Accrual increased proportionately as more centres
opened. In 30 months, 54 patients had been accrued
from 10 of a total of 17 activated sites in Australia and
in Norway by the conclusion of the pilot study (Tables 2
and 3; Figure 1). Australian sites contributed 39 (72%)
of the 54 recruited patients.
Sites
In total 29 sites internationally were approached and
there were 19 positive responses received. All sites that
responded positively reported having appropriate know-
ledge and clinical trials experience including Inter-
national Congress of Harmonization and Good Clinical
Practice (ICHGCP) training.Feasibility forecasts
Feasibility forecasts of the 19 possible major melanoma
treatment centres is summarised in Table 4. Fourteen re-
sponses came from radiation oncologists, with three re-
sponses from neurosurgeons and two responses from
medical oncologists. Nineteen sites, including two inter-
national sites, predicted a total of 133 trial eligible patients
per year (including 108 Australian + 25 international pa-
tients). Two problematic logistic issues were reported at
that time. Two sites reported that they did not have ad-
equate access to radiotherapy and imaging services man-
dated by the study protocol. They were unable to proceed
with the study, leaving 17 sites able to proceed.
Site feasibility forecasts generally overestimated possible
accrual. Only four of seventeen activated sites recruited
the patient number (to within 50%) predicted in their
feasibility forecast during the pilot study accrual period.
Seven of nineteen sites referred to their medical records to
provide their feasibility numbers, the remaining sites pro-
vided feasibility numbers from memory or did not specify
how they arrived at their numbers. Sites that reported pa-
tient estimates by referring to their medical records wereTable 2 Pilot patient recruitment by location
State/country Recruitment up to September 2011






Total 54subsequently found to be more accurate in predicting ac-
crual than those that did not.
The numbers predicted in the feasibility forecasts were
compared with those predicted in the research contract.
Ten of the seventeen activated sites reduced the number
of estimated trial patients from feasibility forecasts to re-
search contracts. Of these 10 sites, two sites were suc-
cessful in achieving the revised target accrual, five sites
randomised some patients but less than specified in their
contracts, and three sites failed to randomise any pa-
tients to the protocol in the accrual period.
Funding
The initial funding application for the pilot study was
successful, which made the whole project possible. In
2006, the ANZMTG and TROG Executive and Scientific
Committees approved protocol development, and prelim-
inary seed funds ($AU18,000) were allocated in support of
the protocol development activities. In 2007, ANZMTG
successfully applied to the Commonwealth of Australia
Department of Health and Aging for support of the pilot
study ($AU281,019). Due to delays in activating sites, a
12 month extension was granted until 30 June 2011.
Demographics
The pilot patient demographic information is presented
(Table 5). Baseline analysis of this population demographic
showed even distribution between the treatment groups (27
patients per arm). The pilot cohort included 62% males and
38% females (n = 54). The age of patients ranged from 26
to 83 years; with the mean age of Australian patients being
slightly older than international patients (61 years vs
56 years). Mean age was relatively balanced between treat-
ment arms (WBRT 60 years vs Observation 58 years). The
majority of patients in the pilot cohort presented with a
solitary brain metastasis (58%), and the remainder with two
metastases (28%) or with three metastases (14%). A
Figure 1 Pilot study patient recruitment over time – April ’09 - October ’11.















Was number of patients
in research contract less
than what was estimated










1# NOR NA 10-15 5 Yes 15 Yes
2* NSW Records 5 5 No 20 Yes
3^ NSW Memory 12 4 Yes 2 No
4* NSW Memory 5-6 6 No 0 No
5* NSW Memory 5-6 2 Yes 0 No
6^ NSW Records 6 2 Yes 1 No
7* NSW Records 3 2 Yes 0 No
8* NSW Memory 8 4 Yes 1 No
9* NSW Memory 4 NS NA 0 No
10* VIC Memory 20 10 Yes 2 No
11* VIC Records 10 5 Yes 1 No
12* QLD Records 2-3 2 Yes 3 Yes
13* QLD Memory 10 10 No 8 Yes
14* QLD Records 2-3 2 Yes 0 No
15* QLD Records 2 2 No 0 No
16* SA N/A NA 2 NA 1 No
17* WA N/A NA NS No 0 No
18^ VIC N/A 10 NA NA NA NA
19# Europe N/A 10 NA NA NA NA
Total 124-133 63 10 54 4/17 Yes
#Department of Medical Oncology.
*Department of Radiation Oncology.
^Department of Neurosurgery.
NOR – Norway; NSW – New South Wales; AU – Australia; VIC – Victoria; QLD – Queensland; SA – South Australia; WA – Western Australia; NA – not applicable;
NS - Not specified.
Fogarty et al. BMC Research Notes 2014, 7:412 Page 4 of 7
http://www.biomedcentral.com/1756-0500/7/412
Table 5 Pilot study patient demographics (54 patients)





Age (years) Mean 61 (AU) Mean 56
(Norway) Range: 26 to 83




Patient presentation at the baseline visit
1 BM 31 57
2 BM 15 27
3 BM 8 14
Extracranial disease – present 36 66
Extracranial disease - absent 18 33
AU - Australia.
BMs – Brain metastases.
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line visit with no evidence of extracranial disease present.
Cumulative overall survival (Table 6; Figure 2) for this
pilot cohort was slightly higher than otherwise reported
for these patients [2]. The study had 6-month overall
survival of 68.5% and 12-month overall survival of
50.0%. There were no trial related significant adverse
events. Data audit after the study was competed revealedFigure 2 Overall survival curve for pilot study patients (N = 54).that data quality was high, especially with completion of
NCF and Quality of Life assessments.Discussion
RCTs are fundamental to progressing evidence–based
medicine. Vibrant trial accrual is essential for timely RCT
completion. Accrual has been difficult in some RCT sce-
narios, for example, WBRT trials of all histologies. Accrual
for a WBRT RCT for a single histology such as melanoma
was thought likely to be even more difficult.
In our pilot study, 54 patients out of a projected 60
were recruited to the study from 10 of 17 activated sites.
Australian sites contributed 39 (72%) of the 54 recruited
patients. International sites were important contributors
to the pilot study. Despite only 54 patients and not the
full 60 patient target being accrued in two years the Trial
Management Committee and Data Safely Monitoring
Committee approved the continuation of the pilot study
to the main trial.Sites
Successful strategies included selecting sites with inves-
tigators having proven accrual in previous melanoma
trials. Another successful strategy was the ANZMTG
coordinating office providing centralised site support
and assisting with study start-up activities (assisting and
coordinating central and local ethics submissions)
which directly accelerated the start of the study at the
individual sites.
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More radiation oncologists completed the feasibilities
than any other clinical speciality, which was consistent
with this being a radiotherapy trial question. As in many
clinical trials, overall recruitment was lower than pre-
dicted by the sites. Site estimates generally overesti-
mated possible accrual with only 4 of 17 sites accurate
to within 50% of target estimates. Sites gathering data
from records gave more accurate estimates of feasibility
than sites estimating from memory. Perhaps central
bodies should insist on data only from medical records
when assessing sites for inclusion in trials.
Sites in general decreased the expected number of pa-
tients to be randomised when their feasibility forecast
was compared with the research contracts. The reasons
for this are not clear but may reflect an increasing
awareness of the difficulty of accrual as the site became
more involved in the trial. In general, the actual number
of patients recruited was more in agreement with the
number specified in the site research contracts than the
initial feasibility forecasts.
There were still some sites which, despite agreeing to
participate in the trial and having a reduced patient target
in their contracts, failed to screen and randomise any trial
patients. The reasons for this are also not clear. Possibly a
perceived lack of clinical equipoise in respect to this trial
question may be the strongest reason. Other reasons why
recruitment was not optimal include ethical consider-
ations, lack of time and interest, new systemic treatments
interfering with brain metastases treatments, and perhaps
conflicts between different medical specialties e.g. medical
versus radiation oncology. These reasons may not have
been apparent to the site investigators when completing
their feasibility forecasts and then the research contracts
for the study. Nevertheless the pilot recruitment compares
favourably with other whole brain radiotherapy trials.
Funding
The success with securing funding was pivotal to this
study. Following the successful completion of the pilot
study, an additional NHMRC grant ($AU591, 010) was
applied for and awarded. In fact, all funding requests for
the main trial were granted in full and no funding applica-
tion has been refused. This approach of securing funding
for a pilot study to assess feasibility, and then applying for
funding for the full study after a successful pilot studyproved to be a worthwhile strategy. The funding agencies
knew that they did not have to commit to funding for a
whole trial that may not complete, and this was attractive
to them. The trial organizers could gain experience, for ex-
ample, by focusing on increasing accrual, without being
distracted by questions that may have arisen if a full trial
was running.
Conclusions
A RCT investigating WBRT after local treatment of mel-
anoma BMs is required. However, WBRT trials are hard
to accrue. A pilot study with a target of 60 patients in
2 years was undertaken. 54 patients were randomised in
30 months. International involvement and funding were
essential. Only 4 of 17 sites were within 50% of their feasi-
bility forecasts. Sites that based these forecasts on a pa-
tient record review rather than from memory were more
reliable. Sites generally decreased their accrual estimates
from feasibility forecasts to the research contracts. The
funding agencies have now funded the full trial which is
now under way, with 143 patients of the target 200 rando-
mised to date.Abbreviations
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